These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 31552599)

  • 1. Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey Study.
    Tetzschner R; Ranjan AG; Schmidt S; Nørgaard K
    Diabetes Ther; 2019 Dec; 10(6):2107-2113. PubMed ID: 31552599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preserved glucose response to low-dose glucagon after exercise in insulin-pump-treated individuals with type 1 diabetes: a randomised crossover study.
    Steineck IIK; Ranjan A; Schmidt S; Clausen TR; Holst JJ; Nørgaard K
    Diabetologia; 2019 Apr; 62(4):582-592. PubMed ID: 30643924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.
    Ranjan A; Nørgaard K; Tetzschner R; Steineck IIK; Clausen TR; Holst JJ; Madsbad S; Schmidt S
    Diabetes Care; 2018 Apr; 41(4):797-806. PubMed ID: 29358493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes.
    Haymond MW; Schreiner B
    Diabetes Care; 2001 Apr; 24(4):643-5. PubMed ID: 11315823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes.
    Haymond MW; DuBose SN; Rickels MR; Wolpert H; Shah VN; Sherr JL; Weinstock RS; Agarwal S; Verdejo AS; Cummins MJ; Newswanger B; Beck RW;
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2994-3001. PubMed ID: 28591776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study.
    Ranjan A; Schmidt S; Damm-Frydenberg C; Steineck I; Clausen TR; Holst JJ; Madsbad S; Nørgaard K
    Diabetes Care; 2017 Jan; 40(1):132-135. PubMed ID: 27797928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon treatment in type 1 diabetes -with focus on restoring plasma glucose during mild hypoglycemia
.
    Ranjan A
    Dan Med J; 2018 Feb; 65(2):. PubMed ID: 29393039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
    Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mini-doses of glucagon to prevent hypoglycemia in children with type 1 diabetes refusing food: a case series.
    Tinti D; Rabbone I
    Acta Diabetol; 2020 Mar; 57(3):359-365. PubMed ID: 31673895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial.
    Haak T; Hanaire H; Ajjan R; Hermanns N; Riveline JP; Rayman G
    Diabetes Ther; 2017 Feb; 8(1):55-73. PubMed ID: 28000140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mini-dose glucagon rescue for mild hypoglycaemia in children with type 1 diabetes: the Brisbane experience.
    Hartley M; Thomsett MJ; Cotterill AM
    J Paediatr Child Health; 2006 Mar; 42(3):108-11. PubMed ID: 16509909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
    Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes.
    Rickels MR; DuBose SN; Toschi E; Beck RW; Verdejo AS; Wolpert H; Cummins MJ; Newswanger B; Riddell MC;
    Diabetes Care; 2018 Sep; 41(9):1909-1916. PubMed ID: 29776987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
    Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraislet hyperinsulinemia prevents the glucagon response to hypoglycemia despite an intact autonomic response.
    Banarer S; McGregor VP; Cryer PE
    Diabetes; 2002 Apr; 51(4):958-65. PubMed ID: 11916913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.